Dr.Reddy's Apremilast API and finished formulation offerings.
Dr. Reddy's is one of the leading API pharma companies supplying Apremilast API globally, and has led the USDMF filing in September 2016 (Form-B) and June 2017 (Amorphous).
Apremilast, is an anti-inflammatory agent modulating a wide range of inflammatory mediators in psoriasis and psoriatic arthritis. Apremilast is indicated for the treatment of active psoriatic arthritis and moderate to severe plaque psoriasis.
Dr. Reddy's amorphous API has been successfully formulated into drug products by various formulators with successful bioequivalence studies and subsequent dossier filing.
To know more about our offerings , please read the technical sheet on Apremilast by filling the contact from below.
Explore other Whitepapers:Know More
Complete el formulario de contacto a continuación para ver el documento técnico